Ann: Updated Strategy and Investor Presentation, page-52

Ah yes, the Astex agreement. The agreement they won't allow RAC to disclose the particulars of. And I'm not surprised to hear of the investigator interest in the miraculous molecule, that's not the concern here.

What I disagree with is what is seemingly your (RAC's?) approach to investor engagement in our company. It seems to be the case that you are only interested in onboarding the minority of retail investors who do the majority of due diligence. This, IMO, is veiled altruism and detrimental to most shareholders. The company should not be in a position to have to raise capital at $1.25 (much less 75c). This is not rewarding long-term holders. And sacrificing a small % of ownership, in what could be truly enormous upside, is not punishing long-term holders.

Zantrene has shown to be synergistic with Amgen's Cafilzomib, Astex' Decitabine, AbbVie's Venetoclax as well as Immunotherapies, TKI's, Anthracyclines... just to name but a few! And yet again, our success seems to be solely reliant on the whims of retail.

Two years ago retail stumped up $30m for various programs, none of which have been seen to completion (yet). It would be hard to fault retail from bowing out this time.